Complete profiling of AR genomic alterations in A031201 cfDNA. Credit score: Nature Communications (2024). DOI: 10.1038/s41467-024-54847-1, https://www.nature.com/articles/s41467-024-54847-1
Revealed in Nature Communications, a brand new examine led by the College of Minnesota Medical College and Duke College discovered {that a} DNA sequencing check for superior prostate most cancers sufferers can distinguish between sufferers with poor and favorable prognoses.
The brand new blood-based check—known as AR-ctDETECT—is designed to detect and analyze small fragments of tumor-derived DNA within the blood of sure sufferers with superior, metastatic prostate most cancers.
On this new examine, the AR-ctDETECT check was used to investigate DNA from greater than 770 blood samples from a section 3 scientific trial of superior prostate most cancers sufferers. The check recognized circulating tumor DNA (ctDNA) in 59% of sufferers with metastatic prostate most cancers. Sufferers with detectable circulating tumor DNA had considerably worse general survival in comparison with these with out. These outcomes exhibit the potential of the AR-ctDETECT check to supply key genetic info to tailor remedies based mostly on related traits amongst sufferers.
“Our AR-ctDETECT test, designed for prostate cancer, shows how valuable these blood tests could be in helping doctors better understand a patient’s cancer and predict how the disease will progress, leading to more personalized treatment plans,” mentioned Scott Dehm, Ph.D., a professor on the U of M Medical College and member of the Masonic Most cancers Middle.
The examine concluded that detecting ctDNA utilizing AR-ctDETECT offers important prognostic insights for sufferers with metastatic prostate most cancers.
“The AR-ctDETECT assay is a comprehensive panel focused on genes relevant to prostate cancer and hormone resistance, particularly the androgen receptor and critical structural alterations not currently detected by other commercial tests,” mentioned Andrew Armstrong, MD, a professor at Duke College College of Drugs, an oncologist with Duke Most cancers Institute and co-senior writer on the examine.
“Incorporating genomic profiling into clinical decision-making may enhance personalized treatment strategies and inform the design of future clinical trials.”
“Our team demonstrated the ability of AR-ctDETECT to effectively identify distinct groups of patients based on their genomic profiles,” mentioned Susan Halabi, Ph.D., a James B. Duke Distinguished Professor of Biostatistics at Duke College College of Drugs.
“Notably, our study is the first to demonstrate, within a phase 3 cohort, that metastatic prostate cancer patients with positive ctDNA treated with standard therapies had worse overall survival compared to ctDNA-negative patients.”
Additional analysis will concentrate on integrating genetic knowledge from the AR-ctDETECT check with affected person scientific knowledge to enhance affected person prognostication. The analysis group additionally plans to judge whether or not the AR-ctDETECT check could possibly be used to foretell affected person outcomes within the context of particular remedies, which could possibly be used sooner or later to information optimum remedy.
Extra info:
AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate most cancers sufferers, Nature Communications (2024). DOI: 10.1038/s41467-024-54847-1. www.nature.com/articles/s41467-024-54847-1
Offered by
College of Minnesota Medical College
Quotation:
DNA sequencing check can predict prognosis for superior prostate most cancers sufferers (2024, December 11)
retrieved 11 December 2024
from https://medicalxpress.com/information/2024-12-dna-sequencing-prognosis-advanced-prostate.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.
